Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells

[1]  W. Willett,et al.  Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts , 2018, Journal of the National Cancer Institute.

[2]  H. Brenner,et al.  Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany , 2017, European Journal of Epidemiology.

[3]  F. Colotta,et al.  Modulation of inflammatory and immune responses by vitamin D. , 2017, Journal of autoimmunity.

[4]  J. Meyerhardt,et al.  Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Kubicka,et al.  Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. , 2017, Cancer treatment reviews.

[6]  H. Nagano,et al.  Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer , 2017, Cancer science.

[7]  Song Liu,et al.  Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study , 2017, JAMA oncology.

[8]  J. Böhm,et al.  Plasma 25-Hydroxyvitamin D3 Levels in Colorectal Cancer Patients and Associations with Physical Activity , 2017, Nutrition and cancer.

[9]  Jeffrey E. Lee,et al.  Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Feinn,et al.  Low Serum Vitamin D: A Surrogate Marker for Advanced Colon Adenoma? , 2016, Journal of clinical gastroenterology.

[11]  G. Prager,et al.  Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Liguori,et al.  Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. , 2016, World journal of gastroenterology.

[13]  T. D. de Gruijl,et al.  Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer , 2016, PloS one.

[14]  M. Merlano,et al.  Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. , 2016, World journal of gastrointestinal oncology.

[15]  C. Mølgaard,et al.  Vitamin D deficiency in Europe: pandemic? , 2016, The American journal of clinical nutrition.

[16]  S. Scala,et al.  Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy , 2016, Cancer Immunology Research.

[17]  G. Brandi,et al.  Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. , 2016, World journal of gastroenterology.

[18]  G. Milano,et al.  The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. , 2015, Critical reviews in oncology/hematology.

[19]  A. Mackensen,et al.  Vitamin D–dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma , 2015, Science Translational Medicine.

[20]  Yangang Wang,et al.  Serum 25-Hydroxyvitamin D Levels and Prognosis in Hematological Malignancies: A Systematic Review and Meta-Analysis , 2015, Cellular Physiology and Biochemistry.

[21]  E. Vokes,et al.  Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab , 2015, Cancer Immunology Research.

[22]  J. Meyerhardt,et al.  Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). , 2015 .

[23]  M. Ziepert,et al.  Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Robien,et al.  The Effects of 1,25-Dihydroxyvitamin D3 on In Vitro Human NK Cell Development from Hematopoietic Stem Cells , 2014, The Journal of Immunology.

[25]  K. Owzar,et al.  25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). , 2014, Journal of the National Cancer Institute.

[26]  H. Brenner,et al.  Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. , 2014, European journal of cancer.

[27]  Jing-quan Li,et al.  Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  B. Koczwara,et al.  Clinical outcomes of vitamin D deficiency and supplementation in cancer patients. , 2013, Nutrition reviews.

[29]  M. Drake,et al.  Vitamin D in the cancer patient , 2013, Current opinion in supportive and palliative care.

[30]  K. Badenhoop,et al.  Vitamin D status and gene transcription in immune cells , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  B. El-Rayes,et al.  Markers of resistance to anti-EGFR therapy in colorectal cancer. , 2013, Journal of gastrointestinal oncology.

[32]  G. Salles,et al.  Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Bessler,et al.  1α,25-Dihydroxyvitamin D3 modulates the interaction between immune and colon cancer cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[34]  D. Hur,et al.  1,25‐Dihydroxyvitamin D3 enhances NK susceptibility of human melanoma cells via Hsp60‐mediated FAS expression , 2011, European journal of immunology.

[35]  S. H. van der Burg,et al.  Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab , 2011, Clinical Cancer Research.

[36]  E. Fearon.  Molecular genetics of colorectal cancer. , 2011, Annual review of pathology.

[37]  C. Rosen.  Vitamin D Insufficiency , 2011 .

[38]  JoAnn E. Manson,et al.  The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.

[39]  D. Hurley,et al.  Vitamin D deficiency in adults: when to test and how to treat. , 2010, Mayo Clinic proceedings.

[40]  C. Mathieu,et al.  Vitamin D: a pleiotropic hormone. , 2010, Kidney international.

[41]  J. Trowbridge,et al.  The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth , 2009, The Journal of Immunology.

[42]  F. J. Ramos,et al.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. , 2009, Cancer treatment reviews.

[43]  M. Holick.  Vitamin D deficiency. , 2007, The New England journal of medicine.

[44]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[45]  F. Bonilla,et al.  Regulation of natural killer cytotoxicity by 1,25-dihydroxyvitamin D3. , 1989, Cellular immunology.

[46]  T. Bekaii-Saab,et al.  A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. , 2018, The oncologist.

[47]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[48]  P. Dhawan,et al.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. , 2016, Physiological reviews.

[49]  L. Hartner,et al.  Vitamin D deficiency in the oncology setting. , 2014, The Journal of community and supportive oncology.